Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $24.13

Shares of Rezolute, Inc. (NASDAQ:RZLT - Get Free Report) have been given an average rating of "Buy" by the eight ratings firms that are currently covering the stock, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $24.13.

A number of equities research analysts have recently issued reports on the stock. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a report on Tuesday, February 4th. Wedbush reissued an "outperform" rating and issued a $112.00 price target on shares of Rezolute in a report on Monday, November 4th. HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of Rezolute in a research report on Wednesday, February 5th. Finally, Guggenheim restated a "buy" rating on shares of Rezolute in a research report on Monday.

Insider Activity at Rezolute

In other news, CFO Daron Evans bought 9,000 shares of the company's stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $4.60 per share, for a total transaction of $41,400.00. Following the completion of the acquisition, the chief financial officer now directly owns 140,900 shares in the company, valued at approximately $648,140. This represents a 6.82 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 18.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Rezolute

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. bought a new stake in Rezolute in the third quarter valued at $42,000. MML Investors Services LLC bought a new stake in Rezolute in the 3rd quarter worth about $57,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Rezolute in the 3rd quarter worth about $65,000. Charles Schwab Investment Management Inc. grew its position in Rezolute by 65.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock worth $112,000 after purchasing an additional 9,000 shares in the last quarter. Finally, Virtu Financial LLC grew its position in Rezolute by 58.0% in the 3rd quarter. Virtu Financial LLC now owns 26,026 shares of the company's stock worth $126,000 after purchasing an additional 9,551 shares in the last quarter. 82.97% of the stock is owned by institutional investors.

Rezolute Price Performance

NASDAQ:RZLT traded up $0.08 on Friday, hitting $4.86. 332,859 shares of the company's stock were exchanged, compared to its average volume of 557,777. The firm has a 50-day moving average price of $4.89 and a 200-day moving average price of $4.90. Rezolute has a 52 week low of $1.05 and a 52 week high of $6.19. The company has a market cap of $281.59 million, a P/E ratio of -3.83 and a beta of 1.10.

Rezolute (NASDAQ:RZLT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.11. On average, research analysts expect that Rezolute will post -0.99 earnings per share for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.